Vivo Bio Tech Secures ₹10.75 Crore Pre-Clinical Testing Contract for Novel Molecule
Vivo Bio Tech Limited has secured a pre-clinical testing contract worth ₹10.75 crores with a leading Indian pharmaceutical and agro-chemical company. The two-year contract involves comprehensive pre-clinical safety and regulatory studies for a novel molecule, including toxicity, mutagenicity, ecotoxicology studies, and analytical services. The studies will be conducted under Section 9(3) requirements for submission to the Central Insecticides Board & Registration Committee (CIBRC). This contract positions Vivo Bio Tech among top Contract Research Organizations in India, demonstrating its capability to deliver integrated pre-clinical solutions meeting national and international regulatory standards.

*this image is generated using AI for illustrative purposes only.
Vivo Bio Tech Limited has announced a significant milestone in its growth trajectory, securing a pre-clinical testing contract valued at ₹10.75 crores. The contract, awarded in collaboration with a leading Indian pharmaceutical and agro-chemical company, positions Vivo Bio Tech among an elite group of Contract Research Organizations (CROs) in India.
Contract Details
The newly secured contract spans up to two years and involves comprehensive pre-clinical safety and regulatory studies for a novel molecule. The scope of work includes:
- Toxicity studies across multiple endpoints
- Mutagenicity evaluations to assess genetic safety
- Ecotoxicology studies for environmental risk assessment
- Comprehensive analytical services
All studies will be conducted under Section 9(3) requirements, with regulatory submissions to the Central Insecticides Board & Registration Committee (CIBRC)—India's apex body for approvals.
Regulatory Compliance and Industry Standing
This contract demonstrates Vivo Bio Tech's capability to deliver integrated pre-clinical solutions that meet both national and international regulatory standards. By undertaking this comprehensive mandate, the company joins a select group of CROs in India with the infrastructure and scientific expertise to handle such complex projects.
Management Commentary
Mr. Chandrasekar Patnaik, Chief Business Officer of Vivo Bio Tech Limited, commented on the achievement: "This milestone reaffirms Vivo Bio Tech's scientific and technical excellence and strengthens our positioning as a trusted research partner for the global life sciences industry. It represents a major step forward in our mission to deliver innovative, reliable, and sustainable research services."
Strategic Implications
The contract underscores Vivo Bio Tech's growing leadership across pharmaceuticals, agrochemicals, biotechnology, and environmental sciences. It aligns with the company's long-term vision of evolving from a drug discovery services provider into a strategic co-innovator with large pharma and biotech companies.
By enabling safer and more effective products to reach global markets, Vivo Bio Tech is paving the way for future collaborations in joint drug discovery and milestone-driven partnerships. This positions the company as a benchmark for next-generation CROs in the industry.
Conclusion
The securing of this significant contract not only boosts Vivo Bio Tech's financial outlook but also enhances its reputation in the pre-clinical research domain. As the company continues to expand its capabilities and secure high-value contracts, it is well-positioned to capitalize on the growing demand for comprehensive pre-clinical testing services in the pharmaceutical and agrochemical sectors.
Historical Stock Returns for Vivo Bio Tech
1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|
+1.25% | +5.69% | +10.48% | -1.55% | +0.96% | -26.52% |